Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene hunt: could sequencing families unlock the roots of mysterious mental illness?

NCT ID NCT07686653

Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates whether sequencing the genomes of patients with early-onset or unusual psychiatric disorders—along with their biological parents—can uncover hidden genetic causes. Researchers aim to find disease-related gene variants in at least 12% of participants aged 3 to 50 who have atypical features like early onset, treatment resistance, or an unclear diagnosis. If successful, this approach could improve understanding and diagnosis of these complex conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that genome sequencing helps diagnose genetic causes for certain psychiatric disorders, potentially guiding more personalized care.
What could go wrong
This is an early-stage study with a modest goal (12% diagnosis rate). It may not find enough genetic links, and results may not apply to all psychiatric conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 255 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The index case and his two parents

Ages

3 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Index case with one or more psychiatric disorders confirmed by a psychiatrist and/or child psychiatrist, whose evaluations may be supplemented as needed as part of their care, and who meets at least ONE of the following criteria for atypicality: * Early age of onset * Unusual course of the disorder (polymorphic/fluctuating) * Treatment resistance * Disorder classified as "unspecified" by the DSM-5 with significant functional impact * Index case aged 3 to 50 years, inclusive * Consent signed by the biological parents and by the "index case, if of legal age" * Index case and their parents enrolled in or eligible for a social security program * Sample collection possible from the index case and their two known biological parents Exclusion Criteria: * Genetic testing previously performed (CGH array, targeted gene testing, gene panel, etc.) * Parent(s) and/or the index case subject to a court-ordered protective measure * The index case and his or her parents have a condition that, in the investigator's opinion, would contraindicate the subject's participation in the study * Presence of an intellectual developmental disorder confirmed by a neuropsychological test or strongly suspected clinically in the index case and/or their parents * Index case with a clear syndromic diagnosis * Index case with a psychiatric disorder already covered by a pre-indication under PFMG2025.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diagnostic strategies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diagnostic strategies Genetic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.